Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Page 3 of 7
Jul 1, 2026AI giant Anthropic, after achieving household-name status in technology, is making bold advances into drug development. This move signals a possible industry-wide transformation as tech behemoths join the AI drug discovery race.
Jun 30, 2026With an explosion of interest in artificial intelligence applications for drug discovery and biomedical research, the official release of Claude Science by Anthropic marks a significant development for the life sciences industry. This new application, tailored for the unique needs of researchers and pharmaceutical professionals, optimizes emerging AI technology to fundamentally reshape how complex scientific problems are tackled.
Jun 29, 2026Edison Scientific, a leader in AI-driven science, and investment firm Population Health Partners are joining forces to develop new biotechs empowered by artificial intelligence. The partnership will harness the potential of AI agents for drug discovery and development, promising to reinvent how biotech startups are founded and scaled in a rapidly evolving scientific landscape.
Jun 27, 2026AI adoption in medicine has accelerated, but clinicians and researchers warn that generative models fall short in explaining their outputs. Transparent, causally rooted systems could bridge the trust gap and improve care, marking a pivotal inflection point for AI in clinical settings.
Jun 26, 2026AI’s technological prowess in healthcare is evident, but many projects stall once initial pilots end. This deep-dive analysis explores why capability alone is not enough, identifying systemic obstacles and offering context on moving from pilot to practice.
Jun 22, 2026While AI’s role in speeding up the initial discovery phase is undeniable, the journey from promising in silico leads to approved drugs remains challenging. This article explores how AI, development processes, and regulatory standards interconnect in modern drug R&D.
Jun 21, 2026The increasing integration of AI in clinical settings has ignited debate about the presence of bias in these tools. While some argue for bias-free models, others contend that AI must recognize and account for real-world disparities to improve care delivery and outcomes.
Jun 17, 2026The partnership between Merck and Protillion represents a substantial investment in artificial intelligence for drug discovery, specifically targeting the development of biologic therapies for unknown indications. As AI continues to revolutionize the way new medicines are designed and optimized, this high-value collaboration may mark a significant turning point in how big pharma approaches early-stage research and portfolio development.
Jun 17, 2026In a climate where failed clinical trials often signal major financial and reputational losses, a biotech company is flipping the narrative—transforming negative trial data into valuable resources for artificial intelligence modeling. This approach exemplifies the increasing integration of AI within health tech and its ongoing potential to redefine success metrics in drug discovery.
Jun 16, 2026Verge Labs has introduced a new artificial intelligence model that addresses patient stratification challenges in neurology clinical trials—a notoriously difficult area for drug development. This in-depth analysis explores what makes the model unique, the problems it aims to solve, and wider consequences for precision medicine, trial optimization, and pharmaceutical innovation.
Jun 16, 2026With artificial intelligence now embedded across the healthcare ecosystem, Elevance Health is concentrating its AI investment on three pivotal goals: simplifying the member experience, enhancing the provider journey, and delivering critical, timely insights to employees. This comprehensive review looks at the company’s practical approach and the broader implications for digital health.
Jun 14, 2026Amid the healthcare sector’s rapid digital transformation and AI adoption, merely achieving data interoperability across platforms is proving insufficient. Experts argue the industry now requires a standardized, trusted representation of clinical information to fully unlock AI’s promise and meaningful care delivery.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.